ChromoTek GmbH pioneers a new class of immunologic research tools derived from single domain camel antibodies for cell biology and proteomics. Founded in 2008 as a spin-off from the Ludwig-Maximilians University Munich (LMU) by a research team around Ulrich Rothbauer, ChromoTek has rapidly developed to become a renowned supplier of innovative reagents as well as a trusted service provider for big pharma. Our management team combines complementary skills and experiences that form a basis for sustained growth.
Our mission is to develop and commercialize better tools for our customers research around the world. With a series of products and services under development, our vision is to become the most recognized leader in the fields of proteomics and live cell imaging.
ChromoTek's products center around the proprietary Chromobody® technology. For that, the innovative single domain camel antibody fragments are either coupled to a matrix (Nano-Traps), to a fluorescent dye (Booster) or fused to a fluorescent protein (Chromobodies®) or are part of an assay system to study protein-protein interactions (F2H-Assay). Their extremely small size and high stability make them ideal reagents for biomolecular research and live cell assays.
Nano-Traps (e.g. GFP-Trap®, RFP-Trap®), are routinely used in thousands of labs all over the world to pulldown tagged proteins and interaction partners thereof from cell extracts, membrane or nuclear preparations. These recombinant binding proteins allow fast, efficient and reliable analytical and preparative one-step purification of proteins for a multitude of downstream applications (Western Blot, ChIP, Mass spec etc.).
Booster are useful to increase the fluorescence signal in various microscopy applications by attaching a stable chemical fluorescent dye to green fluorescent or red fluorescent protein tags. Their advantage is to deliver enhanced sensitivity, especially in cases where photobleaching of samples is a problem.
In genetic fusion with a fluorescent protein, Chromobodies® are functional in living cells where they detect and visualize endogenous target structures in real time. We leverage this unique feature of Chromobodies® to bring high content, dynamic live cell imaging to a next level of performance for medium to high throughput applications (i.e. drug screening).
In addition to Chromobody® based biosensor technology, we have developed a new F2H-Assay to directly visualize protein-protein interactions in live cells. By tethering a fluorescent bait at a defined cellular structure we generate a positional protein-protein interaction biosensor and assay for co-localization of fluorescent prey proteins in living cells. Automated image acquisition and analyses allow us to perform high throughput screens for molecules and drugs perturbing specific protein-protein interactions in the cellular environment and in real time.
To round up our product portfolio, we offer a dedicated selection of high quality monoclonal antibodies.